

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BenQ BM Holding Cayman Corp.

明基醫院集團股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Code: 2581)

CHANGE OF CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of BenQ BM Holding Cayman Corp. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes to the Chief Executive Officer of the Group (the “**CEO**”).

CHANGE OF CHIEF EXECUTIVE OFFICER

In line with the Group’s overall business development direction, the Board is pleased to announce that Ms. LO Tsui-Ling (羅翠凌)(“**Ms. Lo**”) will be appointed as the CEO and a director of Nanjing BenQ Medical Center Co., Ltd. (南京明基醫院有限公司) (“**Nanjing BenQ Hospital**”), a wholly-owned subsidiary of the Company, with effect from July 1, 2026. Immediately prior to Ms. Lo’s appointment, Mr. HSIAO Tze-Jung (“**Mr. Hsiao**”) will cease to be the CEO and a director of Nanjing BenQ Hospital with effect from July 1, 2026. Mr. Hsiao will remain as an executive Director. Mr. Hsiao and the Board confirmed that Mr. Hsiao has no disagreement with the Board and that neither of them is aware of any matter in relation to Mr. Hsiao’s cessation as the CEO that needs to be brought to the attention of the shareholders (the “**Shareholders**”) of the Company.

The biographical details of Ms. Lo are set out below:

Ms. LO Tsui-Ling (羅翠凌), aged 58, joined the Group in April 2009. She was appointed as the president of Suzhou BenQ Hospital on April 1, 2025. Immediately before her appointment as the CEO and a director of Nanjing BenQ Hospital, she was the deputy CEO and vice president of Nanjing BenQ Hospital. Ms. Lo has been working in the Group for more than 15 years and has a commendable history of commitment and contribution to the Group.

Before joining the Group, from September 1994 to December 1999, she served successively as an import and export manager and customs deputy director at several subsidiaries of Qisda Corporation, a controlling shareholder, where she was responsible for import and export management. From January 2000 to April 2009, she served successively as deputy manager and manager of material management at the predecessor of BenQ Materials Corp. (明基材料股份有限公司), a company listed on the Taiwan Stock Exchange (stock code: 8215.TW). After joining the Group in April 2009, Ms. Lo served successively as the division chief and the director of material management, until November 2018. She was subsequently promoted to the executive assistant to the chief executive officer from November 2018 to March 2020. From March 2020 to June 2026, she held the role of vice president of Nanjing BenQ Hospital, and additionally assumed the position of the deputy CEO from August 2024 to June 2026.

Ms. Lo obtained her bachelor's degree in law from TamKang University (淡江大學) in Taiwan in June 1992.

As at the date of this announcement, Ms. Lo is entitled to receive up to 60,000 shares of the Company (the “**Shares**”) pursuant to the exercise of options granted to her under the pre-IPO share option plan of the Company which first became effective in November 2018 (as amended and adopted by the Company on March 22, 2024), subject to the terms and conditions of these options.

Save as disclosed in this announcement, as at the date of hereof, Ms. Lo:

- (i) does not have any interests in the Shares or underlying Shares within the meaning of Part XV of the Securities and Futures Ordinance;
- (ii) has not held any other directorships held in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas, and other major appointments or professional qualifications;
- (iii) does not hold other positions with the Company or other members of the Group; and
- (iv) is not related to any Directors, senior management of the Company, substantial or controlling Shareholders. The Board is not aware of any other matters in relation to Ms. Lo's appointment as the CEO that need to be brought to the attention of the Shareholders nor any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Ms. Lo will not enter into any service agreement with the Company for her new appointment as the CEO and a director of Nanjing BenQ Hospital. Ms. Lo is not entitled to any emoluments for serving as the CEO and a director of Nanjing BenQ Hospital beyond her current remuneration package pursuant to her existing labor contract with the Group.

The Board would like to express its warm welcome to Ms. Lo on her new role as the CEO and a director of Nanjing BenQ Hospital.

By order of the Board
BenQ BM Holding Cayman Corp.
HSIAO Tze-Jung
Executive Director

Hong Kong, June 25, 2026

As at the date of this announcement, the Board comprises Mr. HSIAO Tze-Jung as an executive Director; Mr. CHEN Chi-Hong, Ms. HUNG Chiu-Chin and Dr. WANG Liming as non-executive Directors; and Dr. CHOW Hsing-Yi, Mr. WANG Wen-Tsung and Mr. CHEN Ray-Jade as independent non-executive Directors.